WuXi STA and Antengene partner under MAH scheme

By Flora Southey

- Last updated on GMT

(Image: Getty/JavierHuras)
(Image: Getty/JavierHuras)

Related tags China Asia pacific Wuxi

Antengene has selected CMO WuXi STA to develop and manufacture its mTOR inhibitor product ATG-008 for Chinese and Asia-Pacific markets.

According to the terms, Chinese contract development and manufacturing organisation (CDMO) STA Pharmaceutical (WuXi STA) – a subsidiary of WuXi AppTec – will provide process R&D and manufacturing services for Antengene’s oncology drugs.

The collaboration will focus on Antengene’s Phase II/III mTOR inhibitor candidate ATG-008, designed for the treatment of hepatitis B virus positive advanced hepatocellular carcinoma (HCC) patients, and extend to commercial-stage assets.

Antengene’s pipeline focuses on relapsed/refractory multiple myeloma, lymphomas and solid tumours, as well as colorectal and prostate cancers. Early-phase ATG-527 is being explored for anti-viral indications such as influenza, RSV (respiratory syncytial virus infection), and EB (Epstein Barr) viral-related diseases.

The partnership marks the first time the companies have collaborated, and will target Chinese and Asia-Pacific regions, a WuXi STA spokesperson told us.

According to Antengene CEO Jay Mei, “WuXi STA’s end-to-end CMC [chemistry, manufacturing, and controls] platform enables us to focus on our research and development, and to move our drug candidates from clinical-stage to commercialisation more efficiently. We look forward to a much broader collaboration in the near future.”

The agreement follows on from China’s 2016 Marketing Authorisation Holder (MAH) pilot programme​, which enables good manufacturing practice (GMP)-compliant third party manufacturers, in some provinces, to make pharmaceutical drug products for customers.

Last month​, China approved its first CMO-made new drug since the implementation of the MAH scheme – Ascletis’ viral hepatitis C treatment Ganovo – which had been made by WuXi STA.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers